Neurologian yksikkö
Department of Neurology

Julkaisut 2009
Publications 2009

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Aho L et al. Heavy alcohol consumption and neuropathological lesions: a post-mortem human study.
2 Alafuzoff I et al. Beta-amyloid deposition in brains of subjects with diabetes.
3 Alafuzoff I et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium.
4 Alafuzoff I et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium.
5 Arjamaa O et al. Regulatory role of HIF-1alfa in the pathogenesis of age-related macular degeneration (AMD).
6 Danner N et al. Altered cortical inhibition in Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1).
7 Eriksson K et al. Fosphenytoin.
8 Eskelinen MH et al. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study.
9 Feldman HH et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease.
10 Ferris S et al. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
11 Grunblatt E et al. Tryptophan is a marker of human postmortem brain tissue quality.
12 Halász P et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety from a randomized controlled trial.
13 Helisalmi S et al. Flanking markers of cyntation C (CST3) gene do not show association with Alzheimer's disease.
14 Hicks A. Intracerebral Stem Cell Transplantation in Experimental Stroke Models.
15 Hicks A, Jolkkonen J. Challenges and possibilities of intravascular cell therapy in stroke.
16 Hicks A et al. Cell-based therapies and functional outcome in experimental stroke.
17 Hicks AU et al. Transplantation of human embryonic stem cell-derived neural precursor cells and enriched environment after cortical stroke in rats: cell survival and functional recovery.
18 Hiltunen M et al. Focal cerebral ischemia in rats alters APP processing and expression of Abeta peptide degrading enzymes in the thalamus.
19 Hiltunen M et al. Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: Evidence from experimental studies.
20 Håkansson K et al. Association between mid-life marital status and cognitive function in later life: population based cohort study.
21 Jauhiainen AM et al. Discriminating accuracy of medial temporal lobe volumetry and fMRI in mild cognitive impairment.
22 Julkunen V et al. Cortical thickness analysis to detect progressive mild cognitive impairment: a reference to Alzheimer's disease.
23 Kaarniranta K, Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors.
24 Kaarniranta K, Salminen A. NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD).
25 Kaarniranta K et al. Heat shock proteins as gatekeepers of proteolytic pathways - Implications for age-related macular generation (AMD).
26 Kiviranta PH et al. N(epsilon)-Thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors.
27 Korolainen MA, Pirttilä T. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease.
28 Koskenkorva P et al. Motor cortex and thalamic atrophy in Unverricht-Lundborg disease: Voxel-based morphometric study.
29 Kurl S et al. Plasma N-terminal fragments of natriuretic peptides predict the risk of stroke and atrial fibrillation in men.
30 Kurl S et al. Exercise workload, cardiovascular risk factor evaluation and the risk of stroke in middle-aged men.
31 Kälviäinen R. Clinical trials in status epilepticus-The clinical perspective.
32 Laakso MP et al. Olfactory identification in non-demented elderly population and mild cognitive impairment: a comparison of performance in clinical odor identification versus Boston Naming Test.
33 Lambert JC et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
34 Liapis CD et al. ESVS guidelines. Invasite treatment for carotid stenosis: indications, techniques.
35 Lovestone S et al. AddNeuroMed - The European collaboration for the discovery of novel biomarkers for Alzheimer's disease.
36 Lu A et al. Effects of ubiquillin 1 on the unfolded protein response.
37 Luukkainen-Markkula R et al. Rehabilitation of hemispatial neglect: A randomized study using either arm activation or visual scanning training.
38 Mackenzie IRA et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.
39 Mattsson N et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
40 Monoranu CM et al. pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium.
41 Nordberg A et al. Different cholinesterase inhibitor effects on CSF cholines Alzheimer patients.
42 Nuutinen J et al. Perfusion differences on SPECT and PWI in patients with acuta ischemic stroke.
43 Nuutinen T et al. Clusterin: A forgotten player in Alzheimer's disease.
44 Ojala J et al. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients.
45 Palmio J et al. Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure.
46 Peskind E et al. Safety of lumbar puncture procedures in patients with Alzheimer's disease.
47 Peurala SH et al. Effects of intensive therapy using gait trainer or floor walking exercise early after stroke.
48 Pihlajamäki M et al. Structural and functional MRI in mild cognitive impairment.
49 Pihlajamäki M, Sperling RA. Functional MRi assessment of task-induced deactivation of the default mode network in Alzheimer's disease and at-risk older individuals.
50 Pikkarainen M et al. Hyperphosphorylated Tau in the occipital cortex in aged nondemented subjects.
51 Putkonen P, Kälviäinen R. Ohimolohkoon kohdistuva epilepsiakirurgia on kustannusvaikuttavaa hoitoa.
52 Quinn TJ et al. Evidence-based stroke r-ehabilitation: an expanded guidance document from the european stroke organisation (ESO) guidelines for management of ischaemic stroke and transient ischaemic attack 2008.
53 Rastas S. Vascular Risk Factors in the Very Old with the Emphasis on Mortality and Cognition.
54 Remes A et al. Alzheimerin taudin merkkitekijöiden käyttö muistisairauksien diagnostiikassa.
55 Salminen A, Kaarniranta K. SIRT1 regulates the ribosomal DNA locus: Epigenetic candles twinkle longevity in the Christmas tree.
56 Salminen A, Kaarniranta K. Regulation of the aging process by autophagy.
57 Salminen A, Kaarniranta K. SIRT1: Regulation of longevity via autophagy.
58 Salminen A, Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer's disease.
59 Salminen A, Kaarniranta K. NF-kappaB signaling in the aging process.
60 Salminen A et al. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology.
61 Salminen A et al. Inflammation in Alzheimer's disease: Amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors.
62 Sarajärvi T et al. Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis.
63 Seppänen A et al. Expression of collagen XVII and ubiquitin-binding protein p62 in motor neuron disease.
64 Simmons A et al. MRI measures of Alzheimer's disease and the AddNeuroMed study.
65 Singer D et al. Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer's disease.
66 Sivenius J et al. Modelling the burden of stroke in Finland until 2030.
67 Soininen H. Muistihäiriöpotilaan neurologisten löydösten diagnostiset vihjeet.
68 Solomon A. Cholesterol and Late-Life Cognition. An Epidemiological and Clinical Approach.
69 Solomon A et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later.
70 Solomon A et al. Serum total cholesterol, statins and cognition in non-demented elderly.
71 Solomon A et al. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.
72 Tapiola T et al. Cerebrospinal fluid {beta}-amyloid 42 and Tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
73 van de Pol LA et al. White matter hyperintensities and medial temporal lobe atrophy in clincal subtypes of mild cognitive impairment: the DESCRIPA study.
74 Vepsäläinen S et al. Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
75 Verwey NA et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.
76 Visser PJ et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
77 Viswanathan J et al. An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population.
78 Välimäki TH et al. Caregiver depression is associated with a low sense of coherence and health-related quality of life.
79 Wallin A, Pirttilä T. Biomarkers in vascular dementia.
80 Zhang Y et al. Change of peripheral blood mononuclear cells IFN-gamma, IL-10, and TGF-beta1 mRNA expression levels with active human cytomegalovirus infection in orthotopic liver transplantation.

Neurologian yksikkö Department of Neurology
Julkaisutietokanta 27.5.2010 Publications Data Base 27.5.2010